|
 |
ToremifeneThis page contains recent news articles, when available, and an overview of Toremifene but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Toremifene (when available) Toremifene is an antineoplastic hormonal agent primarily used in the treatment of advanced breast cancer. Toremifene is a nonsteroidal agent that has demonstrated potent antiestrogenic properties in animal test systems. The antiestrogenic effects may be related to its ability to compete with estrogen for binding sites in target tissues such as breast. Toremifene inhibits the induction of rat mammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression of already established DMBA-induced tumors. In this rat model, Toremifene appears to exert its antitumor effects by binding the estrogen receptors. In cytosols derived from human breast adenocarcinomas, Toremifene competes with estradiol for estrogen receptor protein. For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors Mechanism Of Action: Toremifene is a nonsteroidal triphenylethylene derivative. Toremifene binds to estrogen receptors and may exert estrogenic, antiestrogenic, or both activities, depending upon the duration of treatment, animal species, gender, target organ, or endpoint selected. The antitumor effect of toremifene in breast cancer is believed to be mainly due to its antiestrogenic effects, ie, its ability to compete with estrogen for binding sites in the cancer, blocking the growth-stimulating effects of estrogen in the tumor. News Articles on Toremifene GSK 'ì œí”½ìŠ¤' 투여…Virus ë?ŒíŒŒ 미확ì?¸, ë°”ë?¼í?¬ë£¨ë“œ ê¸‰ì—¬ì œí•œ - 06 Jan 2010 ...í•ì•”화학요법 후 1회 ìƒ?승한 FSH 검사 ê²°ê³¼ì—? ì?˜ê±° 투여한 í™”ë ˆìŠ¤í†¤ì •(toremifene citrate ì œì œ)ì?€ 급여로 불ì?¸ì • ë?œë‹¤. 외ìƒ?성 뇌출혈ì—? Nicergoline 10mg ê²½êµ¬ì œ ... 메디컬헤럴드 GTx to cut 28 pct of jobs; sees $1.1 mln Q4 charge - Dec 11, 2009 Last month, the US Food and Drug Administration asked GTx to conduct a second late-stage trial to provide safety and efficacy data for the drug, toremifene ... Reuters GTx Announces Reduction in Force - Dec 13, 2009 ...“The delay of the commercialization of toremifene 80 mg has forced us to make difficult choices,â€? said Dr. Mitchell S. Steiner, CEO of GTx. ... Behavioral Health Central (blog) Biotech's 2009 Stealth Small Cap Rally - Jan 4, 2010 ...the company's New Drug Application [NDA] for toremifene 80 mg to reduce fractures in men with prostate cancer receiving androgen deprivation therapy. ... Seeking Alpha (blog) This Week's Failed Trials, Missed Targets in Biotech - Dec 20, 2009 Memphis-based GTx (GTXI) said it laying off nearly 30 percent of its staff as a result of the delay in the potential commercialization of toremifene 80 mg ... Seeking Alpha (blog) State roundup: Nike looks to grow big in Memphis - Dec 20, 2009 GTx Inc. announced a reduction in workforce of approximately 28 percent reflecting the delay in the potential commercialization of the drug toremifene, ... Nashville Post (subscription) GTx shares fall after delay leads to job cuts - Dec 15, 2009 Last month, GTx had said the Food and Drug Administration wanted additional late-stage study data on the company's bone drug candidate toremifene to ... Financial News USA (press release) Visa, XTO Energy Rise; Oshkosh Falls - Dec 14, 2009 ...the delay in the potential commercialization of toremifene 80 mg to reduce fractures in men with prostate cancer on androgen deprivation therapy. ... Ticker Magazine 'ì‚¬ë¯¸ì˜¨ì •' 외ìƒ?성 뇌출혈ì—? ì“°ë©´ ê¸‰ì—¬ì œí•œ - Dec 30, 2009 ...투여ë?œ XELIRI(ì ¤ë¡œë‹¤+ìº í‘¸í† ) 불ì?¸ì • â–²í•ì•”화학요법 후 1회 ìƒ?승한 FSH 검사 ê²°ê³¼ì—? ì?˜ê±° 투여한 toremifene citrate ì œì œ 불ì?¸ì • 등 7í•ëª© 7사례ë?„ í?¬í•¨ë??다. ... 메디컬투데이 GTx Receives Complete Response Letter from FDA for Toremifene 80 mg New Drug ... - Nov 2, 2009 GTx is pursuing marketing approval in the United States for toremifene 80 mg to reduce fractures in men with prostate cancer on ADT. ... Reuters GTx loss widens in third quarter - Nov 9, 2009 GTx is also determining a new course of action after the FDA's response to its thought-to-be completed trials for toremifene 80 mg. ... Bizjournals.com GTx to Host Conference Call and Webcast to Provide Update on Status of ... - Oct 30, 2009 ...an update regarding the New Drug Application for toremifene 80 mg to reduce fractures in men with prostate cancer on androgen deprivation therapy. ... Reuters The Bull and Bear Story on GTx's Pending Drug Decision: BioBuzz - Oct 27, 2009 Acapodene consists of an 80-mg dose of a drug known as toremifene, used by doctors for years (at a lower dose) to treat breast cancer patients. ... TheStreet.com GTx Closed At New 52-Week Low Monday - Nov 4, 2009 ...announced Monday morning that it received a Complete Response Letter issued from the FDA, regarding its New Drug Application for toremifene 80 mg. ... RTT News GTx Inc. Reports Operating Results (10-Q) - Nov 9, 2009 ...from Ipsen resulting from the achievement of the primary endpoint in the toremifene 80 mg ADT Phase III clinical trial during the first quarter of 2008. ... GuruFocus.com Human Genome rallies, GTX craters - Nov 2, 2009 ...that the Food and Drug Administration will not approve its drug toremifene for prostate cancer until the company is able to supply more clinical data. ... MarketWatch GTx, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new ... - Nov 13, 2009 As of December 31, 2008, the Company is developing toremifene citrate, a selective estrogen receptor modulator (SERM), in two separate clinical programs in ... PR-Inside.com (Pressemitteilung) Event Updates: Cell Therapeutics (CTIC), GTx, Inc. (GTXI), Myriad (MYRX ... - Nov 2, 2009 GTx Inc (GTXI), which was expecting word from the FDA concerning its New drug application (NDA) for Toremifene 80mg tablets received a complete response ... EON: Enhanced Online News (press release) Biotech Blues a Blip? - Nov 2, 2009 ...two Prescription-Drug-User-Fee Act dates arise for acopodene (toremifene) for GTx (GTXI) and Solzira for XenoPort (XNPT, $16.71, Not Rated), ... Barron's Spectrum Pharma: CMS Rules in Favor of Zevalin - Nov 3, 2009 Inc (GTXI), where regulators required the company to conduct another clinical trial for the company's prostate cancer drug toremifene, I contend the FDA ... Seeking Alpha (blog) FDA Approval of GTx Drug Could Come Today - Oct 29, 2009 The drug is an 80-milligram dose of toremifene, which is already used by doctors to treat breast cancer patients. Another 3500 doses of vaccine for the H1N1 ... Memphis Daily News Orion Group Interim Report January-September 2009 - Oct 26, 2009 At the same time, hormone replacement products, such as the Divina(R) range, and toremifene products, such as Fareston(R), were transferred to Specialty ... Trading Markets (press release) GTX 80 收到FDA完整回函 - Nov 2, 2009 ...(GTXI) 8.98 : GTX宣布收到FDA完整回函，有关toremifene 80 mgæ–°è?¯ä¸Šå¸‚申请，å‡?少接å?—é›„æ€§ç´ åŽ»é™¤æ²»ç–—çš„å‰?列腺癌男性患者骨折æ„?外。FDA回函点明ㄧ些临床缺失，包括第三 ... 凤凰网 Prevention drug shows success - May 15, 2005 A new study, however, shows that a drug called toremifene could delay or stop ... Men who took a low dose of toremifene for one year were half as likely to ... USA Today Orion says GTx to seek FDA approval for toremifene citrate drug - Feb 25, 2008 HELSINKI (Thomson Financial) - Orion said US-based licensee GTx will seek permission from the US Food and Drug Administration to start selling the Finnish ... Forbes GTx submits toremifene 80 mg to FDA - Dec 30, 2008 GTx Inc. has submitted a new drug application to the US Food and Drug Administration for toremifene 80 mg, a drug for the prevention of bone fractures in ... Bizjournals.com Prevention drug shows success ; Reduces the risk in precancerous … - May 16, 2005 A new study, however, shows that a drug called toremifene could delay or stop ... Men who took a low dose of toremifene for one year were half as likely to ... Pay-Per-View - USA TODAY - ProQuest Archiver … Top Line Phase III Data Demonstrating Toremifene Citrate 80 mg … - Mar 3, 2008 The reduction of hot flashes in patients treated with toremifene citrate ... Toremifene citrate 80 mg had a favorable safety profile and was well tolerated. ... Free with registration - Business Wire - AccessMyLibrary.com GTx prostate cancer drug needs more study; shares hit - May 23, 2008 The company will now continue the trial of the drug, toremifene, ... The biotechnology company is also testing toremifene in advanced breast cancer and side ... Reuters toremifene - MSN Health & Fitness - Medications - Apr 4, 2005 Before taking toremifene, tell your doctor if you have ever had blood clots. You may not be able to take this medication. Toremifene blocks estrogen from ... MSN Health & Fitness Toremifene Has Beneficial Impact on Lipids, Bone Metabolism: Presented... - Mar 20, 2007 By Joanna Lyford. ST. GALLEN, SWITZERLAND -- March 20, 2007 -- Toremifene has a more favourable impact on lipids and bone metabolism than does anastrozole ... DG News Toremifene claimed to be useful in prostate cancer - Feb 26, 2007 ORLANDO - Biotech group GTX Inc on Friday claimed that its proposed treatment Acapodene has shown that it can mitigate two of the serious side effects that ... earthtimes.org GTx Announces Phase III Clinical Development of Toremifene 20 mg on … - Jul 28, 2008 MEMPHIS, TN, USA (Press Release) - July 28, 2008 - GTx, Inc. (Nasdaq: GTXI), today announced that following a planned safety review, an independent Data ... UroToday International Journal Toremifene Is Effective Therapy for Mastalgia - May 15, 2006 Synopsis: Mastalgia (ie, painful symptoms of the breast) is the most common clinical complaint in women with benign breast disease. Toremifene is a new ... AAFP News Now Toremifene as Effective as Tamoxifen in Preventing Recurrence of... - Dec 15, 2008 By Ed Susman. SAN ANTONIO, Texas -- December 15, 2008 -- The selective oestrogen receptor modulator toremifene appears to be as effective as tamoxifen in ... DG News ASCO PROSTATE: Toremifene May Ease Androgen Deprivation … - Feb 23, 2007 By Peggy Peck, Managing Editor, MedPage Today. KISSIMMEE, Fla., Feb. 23 -- The selective estrogen receptor modulator toremifene (Acapodene) improved lipid ... MedPage Today Toremifene (Systemic). - Oct 27, 2005 Toremifene (TORE-em-i-feen) is a medicine that blocks the effects of the estrogen hormone in the body. It is used to treat breast cancer in women. ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com GTx soars on late-stage cancer study - Feb 25, 2008 Toremifene citrate at 80 milligrams is designed to reduce side effects of a ... GTx said the trial results showed that toremifene citrate 80 mg reduced ... Boston Globe toremifene GTx, Ipsen licensing agreement. - Sep 18, 2006 GTx will be responsible for paying upstream royalties for toremifene. ....Toremifene is being evaluated in phase III trials for the treatment of side ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Toremifene counters the adverse effects of androgen deprivation.(Men's... - Apr 15, 2007 In a planned interim analysis, toremifene (80 mg/day) given orally for 12 months significantly increased BMD in the lumbar spine, hip, and femoral neck in ... Free with registration - Family Practice News - AccessMyLibrary.com Article: Toremifene may prevent prostate cancer in high-risk patients.... - Aug 15, 2005 Toremifene may prevent prostate cancer in high-risk patients.(Rx) ... find Internal Medicine News articles. ORLANDO -- Toremifene citrate, an estrogen ... Pay-Per-View - Internal Medicine News - HighBeam Research toremifene GTx clinical data (phase III) (prostate cancer). - Jan 9, 2006 On 15 December 2005 GTx reported interim results from a 24-month, double-blind, randomized, placebo-controlled phase III trial of toremifene (ACAPODENE), ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones GTx loss widens in 1Q - May 12, 2008 ..."Our first quarter announcement that the toremifene 80 mg Phase III ADT clinical trial met its primary endpoint was a transformational event for GTx," said ... Bizjournals.com Breast Cancer; GTx acquires exclusive rights in the US for toremifene - Jan 11, 2005 2005 JAN 11 - (NewsRx.com & NewsRx.net) -- GTx, Inc., (GTXI), a biopharmaceutical company dedicated to the discovery, development, and commercialization of ... Pay-Per-View - Science Letter - Factiva, from Dow Jones GTx loses more than $13M in 2Q - Aug 5, 2008 ...because of pre-clinical and clinical programs, including the planned filing of a new drug application for the 80 milligram dosage of Toremifene. Bizjournals.com Article: Toremifene counters adverse effects of androgen deprivation.(... - Apr 15, 2007 Toremifene counters adverse effects of androgen deprivation.(Urology) ... find Internal Medicine News articles. ORLANDO -- Toremifene citrate, a selective ... Pay-Per-View - Internal Medicine News - HighBeam Research First Fracture Prevention Study In Men Receiving ADT For Prostate … - Apr 17, 2008 Results of the Phase III ADT clinical trial demonstrate that toremifene citrate ... Patients treated with toremifene citrate 80 mg compared to placebo had ... Medical News Today - Medical News Today (press release) Breast Cancer Risk Factors; Further study is needed to assess toremife... - Dec 13, 2005 2005 DEC 13 - (NewsRx.com) -- Due to early trial termination, researchers in Finland believe further study is needed to assess toremifene for ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Article: Toremifene counters the adverse effects of androgen deprivati... - Apr 15, 2007 Toremifene counters the adverse effects of androgen deprivation.(Men's Health) ... find Family Practice News articles. ORLANDO -- Toremifene citrate ... Pay-Per-View - Family Practice News - HighBeam Research How to take Toremifene from Consumer Reports Health. - Jan 1, 2008 ...tell your doctor and pharmacist if you are allergic to toremifene, or any other medications. tell your doctor and pharmacist what prescription and ... consumerreports.org Intarcia Therapeutics Announces Its Phase 3 Clinical Trial for... - Feb 25, 2005 Estrogen receptor blockers, such as toremifene, act by blocking the ... One group will receive atamestane and toremifene, and the other group will receive ... RedOrbit Learn about Toremifene from Consumer Reports Health. - Jan 1, 2008 Toremifene is used to treat breast cancer that has spread to other parts of the body in women who have experienced menopause ('change of life'; ... consumerreports.org Breast Cancer; Toremifene provides better profiles of lipid metabolism... - Jan 23, 2005 ..."The objective of this study was to evaluate the different profiles of serum lipids resulting from the administration of selective estrogen receptor ... Pay-Per-View - Medical Letter on the CDC & FDA - Factiva, from Dow Jones Medicus NY Awarded Agency of Record for toremifene citrate - Apr 28, 2008 Publicis Healthcare Communications Group (PHCG) announced today that Medicus NY has been awarded agency of record status by GTx, Inc. for the commercial ... Genetic Engineering News - Genetic Engineering News (press release) Breast Cancer; Toremifene provides better profiles of lipid metabolism... - Jan 21, 2005 ..."The objective of this study was to evaluate the different profiles of serum lipids resulting from the administration of selective estrogen receptor ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Toremifene reduced fractures in androgen deprivation-treated prostate... - Apr 16, 2008 SAN DIEGO — Toremifene at 80 mg significantly decreased new morphometric vertebral fractures in men receiving androgen deprivation therapy for prostate ... Endocrine Today Brand Names/Synonyms: Toremifene is also known by the following brand names and/or synonymsAcapodene; Fareston; Farestone; Toremifene; Toremifene Base; Toremifeno [Spanish]; Toremifenum [Latin]; Z-Toremifene Drug Category: Toremifene is categorized under the following by the FDA: Antineoplastic Agents; Selective Estrogen Receptor Modulators; ATC:L02BA02 Dosage Forms: Tablet Absorption: Well absorbed Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]-N,N-dimethyl-ethanamine |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |